Menu
← Oncology Approval Tracker
FDA DECISION ·
Vanflyta + chemotherapy
quizartinib + induction and consolidation chemotherapy · Daiichi Sankyo
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with newly diagnosed FLT3-ITD-positive AML confirmed by an FDA-approved test. Use with standard induction and consolidation, followed by quizartinib maintenance.
LAMPGEN ANALYSIS
Why it matters
The approval spanned multiple treatment phases for a specific FLT3 alteration.
What research teams should watch
Return FLT3-ITD testing promptly and plan phase-specific dosing and QT monitoring.
Related study operations checklist
See the staffing responsibilities, timing, and handoff questions for this study setting.
Newly diagnosed, molecularly selected AMLPRIMARY RECORDS